You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Marburg Virus Prophylactic Medical Countermeasure
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus
SBC: EVRYS BIO LLC Topic: CBD18A002In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of the US Homeland. Practically all threat agents of biological origin (except forcertain non-proteinaceous toxins, typically produced by marine organisms and fungi) have their structure and vital function ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Circulating Diagnostic Markers of Infectious Disease
SBC: PATHOVACS INCORPORATED Topic: CBD18A001The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-d ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Marburg Virus Prophylactic Medical Countermeasure
SBC: Flow Pharma, Inc. Topic: CBD18A002Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases
SBC: CFD RESEARCH CORPORATION Topic: CBD18A001In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
System for Nighttime and Low-Light Face Recognition
SBC: POLARIS SENSOR TECHNOLOGIES INC Topic: SOCOM18A001The objective of this proposal is to develop instrumentation and algorithms for acquiring facial features for facial recognition in low- and no-light conditions.We will use cross-spectrum matching by exploiting infrared polarimetric imagery which tends to show features that match more closely visible imagery than conventional infrared.In addition to thermal infrared, we will also test subjects in ...
STTR Phase I 2018 Department of DefenseSpecial Operations Command -
Human Performance Optimization: Ketone Esters for Optimization of Operator Performance in Hypoxia
SBC: HVMN Inc. Topic: SOCOM17C001In the setting of altitude-induced hypoxia, operator cognitive capacity degrades and can compromise both individual and team performance. This degradation is linked to falling brain energy (ATP) levels and an increased reliance on anaerobic energy production from glucose. Ketone bodies are the evolutionary alternative substrate to glucose for brain metabolic requirements; previous studies have sho ...
STTR Phase I 2018 Department of DefenseSpecial Operations Command -
Novel Mixed-mode TCAD-Commercial PDK Integrated Flow for Radiation Hardening By Design
SBC: CFD RESEARCH CORPORATION Topic: DTRA16A003Cost-effective application of advanced commercial electronics technologies in DoD space systems requires early development of radiation-hardened-by-design (RHBD) techniques, and use of simulations is critical to the efficiency of this process. CFDRC has developed an integrated, mixed-mode simulation approach allowing their NanoTCAD device physics simulator to interface with commercial circuit simu ...
STTR Phase I 2017 Department of DefenseDefense Threat Reduction Agency -
Development of powder bed printing (3DP) for rapid and flexible fabrication of energetic material payloads and munitions
SBC: MAKEL ENGINEERING, INC. Topic: DTRA16A001This program will demonstrate how additive manufacturing technologies can be used with reactive and high energy materials to create rapid and flexible fabrication of payload and munitions. Our primary approach to this problem will be to use powder bed binder printing techniques to print reactive structures. The anticipated feedstock will consist of composite particles containing all reactant spe ...
STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency -
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications
SBC: GENECAPTURE, INC. Topic: CBD15C001The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula
STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense